Clinical trial
Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis
NCT00051662 · XOMA (US) LLC, Industry · Completed
Key facts
| NCT number | NCT00051662 |
|---|---|
| Title | Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis |
| Official title | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Pharmacokinetics of Efalizumab in Subjects With Psoriatic Arthritis |
| Lead sponsor | XOMA (US) LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Psoriatic Arthritis |
| Intervention type | Drug |
| Interventions | efalizumab |
| Enrollment | 45 |
| Completion | Feb 1, 2004 |
| First posted | Jan 16, 2003 |
| Last update posted | Jun 24, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: